J&J Spots Potential Of Fate’s Stem Cells, Signs Cancer Deal Worth Up To $3bn
Another Next-Generation Approach to CAR-Ts
Executive Summary
Investment from Janssen helps to validate the platform developed by the San Diego-based company.
You may also be interested in...
Fate Uncertain As Cell Therapy Biotech Pulls Out Of J&J Deal, Restructures
The company is discontinuing its lead clinical programs and planning major layoffs as it seeks to reprioritize its pipeline and extend cash runway.
Working Toward A Cure: Janssen’s Multiple Myeloma Strategy
Janssen’s Mark Wildgust explained how the Johnson & Johnson subsidiary is pushing forward with novel therapeutics and combination regimens with the goal of eliminating myeloma in the first line.
Adaptimmune/Genentech Deal Gives Powerful Push To Solid Tumor Cell Therapies
Adaptimmune is getting a leg up in the race to develop iPSC-derived allogeneic cell therapies in a deal with the Roche subsidiary worth potentially more than $3bn.